patents.google.com

SG11202104217QA - Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof - Google Patents

  • ️Fri May 28 2021

SG11202104217QA - Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof - Google Patents

Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof

Info

Publication number
SG11202104217QA
SG11202104217QA SG11202104217QA SG11202104217QA SG11202104217QA SG 11202104217Q A SG11202104217Q A SG 11202104217QA SG 11202104217Q A SG11202104217Q A SG 11202104217QA SG 11202104217Q A SG11202104217Q A SG 11202104217QA SG 11202104217Q A SG11202104217Q A SG 11202104217QA Authority
SG
Singapore
Prior art keywords
antibodies
family
sequence similarity
similarity
sequence
Prior art date
2019-01-02
Application number
SG11202104217QA
Inventor
Bongcheol Kim
Wonkyum Kim
Dong Sik Kim
Jae-Keun Lee
Jeongwon Yoon
Junho Chung
Junyeong Jin
Original Assignee
Neuracle Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
2019-01-02
Filing date
2019-12-31
Publication date
2021-05-28
2019-12-31 Application filed by Neuracle Science Co Ltd filed Critical Neuracle Science Co Ltd
2021-05-28 Publication of SG11202104217QA publication Critical patent/SG11202104217QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202104217QA 2019-01-02 2019-12-31 Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof SG11202104217QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962787711P 2019-01-02 2019-01-02
US201962838190P 2019-04-24 2019-04-24
PCT/IB2019/061461 WO2020141452A1 (en) 2019-01-02 2019-12-31 Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof

Publications (1)

Publication Number Publication Date
SG11202104217QA true SG11202104217QA (en) 2021-05-28

ID=71407016

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104217QA SG11202104217QA (en) 2019-01-02 2019-12-31 Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof

Country Status (11)

Country Link
US (1) US20220144932A1 (en)
EP (1) EP3906260A4 (en)
JP (2) JP2022515960A (en)
KR (2) KR20240049652A (en)
CN (2) CN113195533B (en)
AU (1) AU2019418141A1 (en)
BR (1) BR112021008114A2 (en)
CA (1) CA3117619A1 (en)
MX (1) MX2021004504A (en)
SG (1) SG11202104217QA (en)
WO (1) WO2020141452A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2838814T3 (en) * 2012-02-15 2021-07-02 Neuracle Science Co Ltd FAM19A5 for use in the diagnosis and treatment of CNS damage
CA3115797A1 (en) * 2018-10-16 2020-04-23 Neuracle Science Co., Ltd. Use of anti-fam19a5 antibodies
EP4367128A1 (en) * 2021-07-08 2024-05-15 Neuracle Science Co., Ltd. Polypeptide inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2838814T3 (en) 2012-02-15 2021-07-02 Neuracle Science Co Ltd FAM19A5 for use in the diagnosis and treatment of CNS damage
KR101802411B1 (en) * 2015-02-17 2017-11-29 울산대학교 산학협력단 Composition for preventing or treating of obesity comprising FAM19A5 and screening method for agent for treatment of obesity using the same
KR102431830B1 (en) 2016-11-07 2022-08-16 주식회사 뉴라클사이언스 Anti-family 19, member A5 antibodies with sequence similarity and methods of use thereof
US11746149B2 (en) * 2017-06-27 2023-09-05 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma
CA3067923A1 (en) * 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. Anti-fam19a5 antibodies and uses thereof
KR102454460B1 (en) * 2017-06-27 2022-10-17 주식회사 뉴라클사이언스 Use of anti-FAM19A5 antibody for the treatment of cancer
KR102340352B1 (en) * 2017-06-27 2021-12-21 주식회사 뉴라클사이언스 Use of an anti-FAM19A5 antibody for the treatment of fibrosis
WO2019207513A1 (en) * 2018-04-24 2019-10-31 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain
CN119662732A (en) * 2018-05-08 2025-03-21 纽洛可科学有限公司 Adeno-associated virus (AAV) delivery of anti-FAM19A5 antibodies

Also Published As

Publication number Publication date
CA3117619A1 (en) 2020-07-09
US20220144932A1 (en) 2022-05-12
CN113195533B (en) 2024-04-26
JP2022515960A (en) 2022-02-24
EP3906260A1 (en) 2021-11-10
CN113195533A (en) 2021-07-30
KR20240049652A (en) 2024-04-16
MX2021004504A (en) 2021-10-01
EP3906260A4 (en) 2022-08-31
AU2019418141A1 (en) 2021-05-27
WO2020141452A1 (en) 2020-07-09
KR102656738B1 (en) 2024-04-16
CN117964756A (en) 2024-05-03
KR20210068608A (en) 2021-06-09
JP2023052664A (en) 2023-04-11
BR112021008114A2 (en) 2021-08-31

Similar Documents

Publication Publication Date Title
EP3790898A4 (en) 2022-03-02 Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
IL276830A (en) 2020-10-29 Anti-claudin 18.2 antibodies and uses thereof
SG11202007074PA (en) 2020-08-28 Anti-claudin 18.2 antibodies and uses thereof
SG11202110145SA (en) 2021-10-28 Antibodies against sars-cov-2 and methods of using the same
IL276731A (en) 2020-09-30 Anti-cd73 antibodies and methods of use thereof
EP3878863A4 (en) 2022-06-22 Anti-claudin18.2 antibody and use thereof
IL278821A (en) 2021-01-31 Anti-sirpa antibodies and methods of use thereof
SG11202108398YA (en) 2021-08-30 Anti-claudin 18 antibodies and methods of use thereof
SG11202010909RA (en) 2020-12-30 Anti-msr1 antibodies and methods of use thereof
ZA202106880B (en) 2023-02-22 Anti-claudin 18.2 antibody and application thereof
ZA202103061B (en) 2022-10-26 Anti-cldn18.2 antibody and uses thereof
EP4335874A3 (en) 2024-05-29 Anti-hla-g antibodies and use thereof
EP3645044A4 (en) 2021-04-28 Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of glaucoma
IL270214A (en) 2020-01-30 Anti-sortilin antibodies and methods of use thereof
IL279648A (en) 2021-03-01 Anti-sirp-beta1 antibodies and methods of use thereof
SG11202108734VA (en) 2021-09-29 Anti-trem2 antibodies and methods of use thereof
SG11202104217QA (en) 2021-05-28 Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
IL290741A (en) 2022-04-01 Anti-cd96 antibodies and methods of use thereof
IL262747A (en) 2018-12-31 Anti-kv1.3 antibodies, and methods of production and use thereof
SG11202108403UA (en) 2021-08-30 Anti-clec2d antibodies and methods of use thereof
IL289952A (en) 2022-03-01 Anti-ms4a4a antibodies and methods of use thereof
IL280338A (en) 2021-03-01 Anti-siglec-5 antibodies and methods of use thereof
IL291461A (en) 2022-05-01 Anti-alpha-synuclein antibodies and methods of use thereof
IL283884A (en) 2021-07-29 Anti-il-36 antibodies and methods of use thereof
IL279227A (en) 2021-01-31 Anti-siglec-7 antibodies and methods of use thereof